文献速递肺外科

微创肺叶切除术与立体定向消融放疗治疗I期非小细胞肺癌的比较

Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

这项回顾性队列研究从12家荷兰医院纳入2014-2015年临床I期非小细胞肺癌患者597例,比较微创肺叶切除术(MIL,n=356)与立体定向消融放疗(SABR,n=241)的结局;未校正分析显示MIL的OS和PFS更优、LCSS相似,倾向评分加权分析未显示显著差异,该可行性研究把握度不足。

要点

  • 未校正5年PFS:MIL组63% vs SABR组30%;OS:MIL组72% vs SABR组38%;LCSS:MIL组81% vs SABR组76%。
  • 倾向评分加权分析未显示MIL与SABR在OS、PFS或LCSS上有显著差异。
  • 该可行性研究把握度不足,研究正在扩展至≥1880例以比较总体及特定特征患者的最佳治疗。

核心结论

  • 未校正分析显示MIL的OS和PFS优于SABR,LCSS相似,但该可行性研究把握度不足以通过倾向评分方法证明显著差异。
  • 该研究正在扩展至包括超过一半的荷兰医院,以将人群扩大至≥1880例患者,不仅确定I期NSCLC患者的总体最佳治疗,也评估具有特定特征患者组的首选治疗。

研究设计与样本

  • 回顾性队列研究,数据来自12家荷兰医院数据库,纳入2014-2015年临床I期NSCLC接受MIL或SABR治疗的患者。
  • 共纳入597例患者,其中MIL组356例,SABR组241例。
  • 比较MIL与SABR的无进展生存(PFS)、总生存(OS)和肺癌特异性生存(LCSS)。

主要发现

  • MIL组106例(30%)死亡,SABR组142例(59%)死亡。
  • 未校正5年PFS:MIL组63% vs SABR组30%;OS:MIL组72% vs SABR组38%;LCSS:MIL组81% vs SABR组76%。
  • 倾向评分加权分析未显示MIL与SABR在OS上有显著差异[HR 0.74(95%CI 0.43-1.29)]。
  • 倾向评分加权分析未显示MIL与SABR在PFS上有显著差异[HR 0.74(95%CI 0.42-1.32)]。
  • 倾向评分加权分析未显示MIL与SABR在LCSS上有显著差异[HR 0.81(95%CI 0.42-1.59)]。

局限性

  • 该可行性研究把握度不足,无法通过倾向评分方法证明显著差异。
  • 研究正在扩展至包括超过一半的荷兰医院,以将人群扩大至≥1880例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A minimally invasive lobectomy (MIL) is the standard treatment for stage I non-small cell lung cancer (NSCLC) in medically operable patients. Stereotactic ablative radiotherapy (SABR) is recommended for inoperable patients and has been proposed as a potential alternative for operable patients as well. Here, we present the results of a feasibility study in preparation for a nationwide retrospective cohort study, comparing outcomes between both treatment modalities. METHODS: In this retrospective cohort study, data from patients with clinical stage I NSCLC treated with MIL or SABR in 2014-2015 were retrieved from databases from 12 Dutch hospitals. Progression-free survival (PFS), overall survival (OS) and lung cancer-specific survival (LCSS) were compared between MIL and SABR. RESULTS: A total of 597 patients with clinical stage I NSCLC treated with MIL (n = 356) or SABR (n = 241) were included. In total, 106 (30%) patients had died in the MIL group and 142 (59%) in the SABR group. After MIL and SABR, unadjusted 5-year PFS was 63% and 30%, OS was 72% and 38% and LCSS was 81% and 76%, respectively. Propensity score-weighted analyses did not show significant differences between MIL and SABR in OS [hazard ratios (HR) 0.74 (95% confidence interval (CI) 0.43-1.29)], PFS [HR 0.74 (95% CI 0.42-1.32)] or LCSS [HR 0.81 (95% CI 0.42-1.59)]. CONCLUSIONS: Unadjusted analyses revealed superior OS and PFS for MIL and similar LCSS, but this feasibility study was not sufficiently powered to demonstrate significant differences using propensity score methodology. Therefore, this study is currently being extended to include more than half of Dutch hospitals in order to enlarge the population to ≥1880 patients, not only to determine the best treatment for patients with stage I NSCLC overall, but also to assess the preferred treatment for patient groups with specific characteristics.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. de Ruiter JC, van Diessen JNA, Smit EF, et al. Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2022. PMID: 35348664. doi:10.1093/ejcts/ezac118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。